Literature DB >> 10233961

Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors.

J C Johnston1, M Gasmi, L E Lim, J H Elder, J K Yee, D J Jolly, K P Campbell, B L Davidson, S L Sauter.   

Abstract

The development of gene delivery vectors based on feline immunodeficiency virus (FIV) is an attractive alternative to vectors based on primate sources for the delivery of genes into humans. To investigate the requirements for efficient transduction of dividing and nondividing cells by vector particles based on FIV, a series of packaging and vector constructs was generated for which viral gene expression was minimized and from which unnecessary cis-acting sequences were deleted. Pseudotyped vector particles produced in 293T cells were used to transduce various target cells, including contact-inhibited human skin fibroblasts and growth-arrested HT1080 cells. FIV vectors in which the U3 promoter was replaced with the cytomegalovirus promoter gave rise to over 50-fold-higher titers than FIV vectors containing the complete FIV 5' long terminal repeat (LTR). Comparison of the transduction efficiencies of vectors containing different portions of the FIV Gag coding region indicates that at least a functional part of the FIV packaging signal (Psi) is located within an area which includes the 5' LTR and the first 350 bp of gag. Transduction efficiencies of vectors prepared without FIV vif and orf2 accessory gene expression did not differ substantially from those of vectors prepared with accessory gene expression in either dividing or nondividing cells. The requirement for FIV rev-RRE was, however, demonstrated by the inefficient production of vector particles in the absence of rev expression. Together, these results demonstrate the efficient transduction of nondividing cells in vitro by a multiply attenuated FIV vector and contribute to an understanding of the minimum requirements for efficient vector production and infectivity. In addition, we describe the ability of an FIV vector to deliver genes in vivo into hamster muscle tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233961      PMCID: PMC112543     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.

Authors:  R A Olmsted; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.

Authors:  Y Takeuchi; F L Cosset; P J Lachmann; H Okada; R A Weiss; M K Collins
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Analysis of the vif gene of feline immunodeficiency virus.

Authors:  B L Shacklett; P A Luciw
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

4.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.

Authors:  R B DuBridge; P Tang; H C Hsia; P M Leong; J H Miller; M P Calos
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

5.  Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission.

Authors:  J K Yamamoto; H Hansen; E W Ho; T Y Morishita; T Okuda; T R Sawa; R M Nakamura; N C Pedersen
Journal:  J Am Vet Med Assoc       Date:  1989-01-15       Impact factor: 1.936

6.  Identification of a cis-acting element in human immunodeficiency virus type 2 (HIV-2) that is responsive to the HIV-1 rev and human T-cell leukemia virus types I and II rex proteins.

Authors:  N Lewis; J Williams; D Rekosh; M L Hammarskjöld
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

7.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.

Authors:  J K Yee; A Miyanohara; P LaPorte; K Bouic; J C Burns; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Molecular cloning of feline immunodeficiency virus.

Authors:  R A Olmsted; A K Barnes; J K Yamamoto; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

10.  Nucleotide sequence and genomic organization of feline immunodeficiency virus.

Authors:  R L Talbott; E E Sparger; K M Lovelace; W M Fitch; N C Pedersen; P A Luciw; J H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more
  56 in total

1.  Bad for cats, good for humans? Modified feline immunodeficiency virus for gene therapy.

Authors:  R G Crystal
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

Review 3.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Optimization of feline immunodeficiency virus vectors for RNA interference.

Authors:  Scott Q Harper; Patrick D Staber; Christine R Beck; Sarah K Fineberg; Colleen Stein; Dalyz Ochoa; Beverly L Davidson
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 5.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

6.  Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.

Authors:  Melinda A Brindley; Laura Hughes; Autumn Ruiz; Paul B McCray; Anthony Sanchez; David A Sanders; Wendy Maury
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

7.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

8.  Feline immunodeficiency virus as a gene transfer vector in the rat nucleus tractus solitarii.

Authors:  L H Lin; J E Langasek; L S Talman; O M Taktakishvili; W T Talman
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

9.  Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.

Authors:  J M Staber; M J Pollpeter; C-G Anderson; M Burrascano; A L Cooney; P L Sinn; D T Rutkowski; W C Raschke; P B McCray
Journal:  Gene Ther       Date:  2017-09-14       Impact factor: 5.250

10.  Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Authors:  Aymeric de Parseval; Udayan Chatterji; Peiqing Sun; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.